Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals has received FDA Fast Track designation for its brain cancer imaging agent TLX101-CDx, aimed at improving glioma diagnosis and management. The company has also announced a collaboration with UCSF for joint development and commercialization, as well as a partnership with PharmaLogic for manufacturing and distribution in the U.S. market, with the goal of making the advanced imaging agent widely available to patients upon regulatory approval.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
